Fatigue Score News Today

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

The approval was based on data from the phase 3 ALPHA trial, which evaluated danicopan as add-on therapy to ravulizumab or eculizumab in adults with PNH and clinically significant EVH.

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is...

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...

Agios Pharmaceuticals Inc.’s stock soared 19.6% early Wednesday, after the biotech announced positive results from a Phase 3 trial of a treatment for a rare...

03.01.2024 - –Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Baseline in Both FACIT-Fatigue Score and Hemoglobin ... Seite 1

Topline Results: Phase 3 ENERGIZE Study of PYRUKYND® in Thalassemia January 3, 2024 ...

Agios Pharmaceuticals Inc AGIO says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved…

Agios Pharmaceuticals Inc (NASDAQ:AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or...

No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 -- AIM ImmunoTech Inc.   today announced the last subject has completed treatment...